Literature DB >> 27451809

Utility of Novel Plasma Metabolic Markers in the Diagnosis of Pediatric Tuberculosis: A Classification and Regression Tree Analysis Approach.

Lin Sun1, Jie-Qiong Li1, Na Ren1, Hui Qi1, Fang Dong1, Jing Xiao1, Fang Xu1, Wei-Wei Jiao1, Chen Shen1, Wen-Qi Song1, A-Dong Shen1.   

Abstract

Although tuberculosis (TB) has been the greatest killer due to a single infectious disease, pediatric TB is still hard to diagnose because of the lack of sensitive biomarkers. Metabolomics is increasingly being applied in infectious diseases. But little is known regarding metabolic biomarkers in children with TB. A combination of a NMR-based plasma metabolic method and classification and regression tree (CART) analysis was used to provide a broader range of applications in TB diagnosis in our study. Plasma samples obtained from 28 active TB children and 37 non-TB controls (including 21 RTIs and 16 healthy children) were analyzed by an orthogonal partial least-squares discriminant analysis (OPLS-DA) model, and 17 metabolites were identified that can separate children with TB from non-TB controls. CART analysis was then used to choose 3 of the markers, l-valine, pyruvic acid, and betaine, with the least error. The sensitivity, specificity, and area under the curve (AUC) of the 3 metabolites is 85.7% (24/28, 95% CI, 66.4%, 95.3%), 94.6% (35/37, 95% CI, 80.5%, 99.1%), and 0.984(95% CI, 0.917, 1.000), respectively. The 3 metabolites demonstrated sensitivity of 82.4% (14/17, 95% CI, 55.8%, 95.3%) and specificity of 83.9% (26/31, 95% CI, 65.5%, 93.9%), respectively, in 48 blinded subjects in an independent cohort. Taken together, the novel plasma metabolites are potentially useful for diagnosis of pediatric TB and would provide insights into the disease mechanism.

Entities:  

Keywords:  NMR; children; diagnosis; metabolomics; plasma; tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27451809     DOI: 10.1021/acs.jproteome.6b00228

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  10 in total

1.  Biomarkers for diagnosis of childhood tuberculosis: A systematic review.

Authors:  Toyin Omotayo Togun; Emily MacLean; Beate Kampmann; Madhukar Pai
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

2.  A classification modeling approach for determining metabolite signatures in osteoarthritis.

Authors:  Jason S Rockel; Weidong Zhang; Konstantin Shestopaloff; Sergei Likhodii; Guang Sun; Andrew Furey; Edward Randell; Kala Sundararajan; Rajiv Gandhi; Guangju Zhai; Mohit Kapoor
Journal:  PLoS One       Date:  2018-06-29       Impact factor: 3.240

3.  Identification of serum biomarkers for active pulmonary tuberculosis using a targeted metabolomics approach.

Authors:  Yonggeun Cho; Youngmok Park; Bora Sim; Jungho Kim; Hyejon Lee; Sang-Nae Cho; Young Ae Kang; Sang-Guk Lee
Journal:  Sci Rep       Date:  2020-03-02       Impact factor: 4.379

4.  Discovery and validation of an NMR-based metabolomic profile in urine as TB biomarker.

Authors:  José Luis Izquierdo-Garcia; Patricia Comella-Del-Barrio; Ramón Campos-Olivas; Raquel Villar-Hernández; Cristina Prat-Aymerich; Maria Luiza De Souza-Galvão; Maria Angeles Jiménez-Fuentes; Juan Ruiz-Manzano; Zoran Stojanovic; Adela González; Mar Serra-Vidal; Esther García-García; Beatriz Muriel-Moreno; Joan Pau Millet; Israel Molina-Pinargote; Xavier Casas; Javier Santiago; Fina Sabriá; Carmen Martos; Christian Herzmann; Jesús Ruiz-Cabello; José Domínguez
Journal:  Sci Rep       Date:  2020-12-18       Impact factor: 4.379

5.  Targeted metabolomics analysis of serum and Mycobacterium tuberculosis antigen-stimulated blood cultures of pediatric patients with active and latent tuberculosis.

Authors:  Druszczynska Magdalena; Seweryn Michal; Sieczkowska Marta; Kowalewska-Pietrzak Magdalena; Pankowska Anna; Godkowicz Magdalena; Szewczyk Rafał
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

Review 6.  Tuberculous Granuloma: Emerging Insights From Proteomics and Metabolomics.

Authors:  Abisola Regina Sholeye; Aurelia A Williams; Du Toit Loots; A Marceline Tutu van Furth; Martijn van der Kuip; Shayne Mason
Journal:  Front Neurol       Date:  2022-03-21       Impact factor: 4.003

7.  Combining metabolome and clinical indicators with machine learning provides some promising diagnostic markers to precisely detect smear-positive/negative pulmonary tuberculosis.

Authors:  Xin Hu; Jie Wang; Yingjiao Ju; Xiuli Zhang; Wushou'er Qimanguli; Cuidan Li; Liya Yue; Bahetibieke Tuohetaerbaike; Ying Li; Hao Wen; Wenbao Zhang; Changbin Chen; Yefeng Yang; Jing Wang; Fei Chen
Journal:  BMC Infect Dis       Date:  2022-08-25       Impact factor: 3.667

8.  Urine NMR-based TB metabolic fingerprinting for the diagnosis of TB in children.

Authors:  Patricia Comella-Del-Barrio; José Luis Izquierdo-Garcia; Jacqueline Gautier; Mariette Jean Coute Doresca; Ramón Campos-Olivas; Clara M Santiveri; Beatriz Muriel-Moreno; Cristina Prat-Aymerich; Rosa Abellana; Tomas M Pérez-Porcuna; Luis E Cuevas; Jesús Ruiz-Cabello; José Domínguez
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

9.  Integration of metabolomics and transcriptomics reveals novel biomarkers in the blood for tuberculosis diagnosis in children.

Authors:  Noton K Dutta; Jeffrey A Tornheim; Kiyoshi F Fukutani; Mandar Paradkar; Rafael T Tiburcio; Aarti Kinikar; Chhaya Valvi; Vandana Kulkarni; Neeta Pradhan; Shri Vijay Bala Yogendra Shivakumar; Anju Kagal; Akshay Gupte; Nikhil Gupte; Vidya Mave; Amita Gupta; Bruno B Andrade; Petros C Karakousis
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

10.  Discovery of serum biomarkers for diagnosis of tuberculosis by NMR metabolomics including cross-validation with a second cohort.

Authors:  R Conde; R Laires; L G Gonçalves; A Rizvi; C Barroso; M Villar; R Macedo; M J Simões; S Gaddam; P Lamosa; L Puchades-Carrasco; A Pineda-Lucena; A B Patel; S C Mande; S Banerjee; M Matzapetakis; A V Coelho
Journal:  Biomed J       Date:  2021-07-24       Impact factor: 7.892

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.